Voices
Nieves Martinez Lago: Balancing Efficacy and Safety of Tarlatamab in Medullary Thyroid Carcinoma
Nieves Martinez Lago/LinkedIn

Nieves Martinez Lago: Balancing Efficacy and Safety of Tarlatamab in Medullary Thyroid Carcinoma

Nieves Martinez Lago, Specialist in the Field (FEA) of Medical Oncology at University Hospital Complex of Santiago de Compostela, shared a post on X:

“Tarlatamab (DLL3) in MTC

  • Case series (n=4): heavily pretreated MTC
  • ORR 67% (2 PR, 1 SD evaluable)
  • 100% clinical/biochemical activity signal

Safety concerns: G≥3 TRAEs in all pts (CRS, ICANS, G5 perforation)

Promising activity, but dosing/safety need optimization ”

Title: Preliminary Safety and Efficacy of Tarlatamab in Medullary Thyroid Carcinoma

Authors: Thomas Roberts, Kartik Sehgal, Steven DuBois, Jason Hornick, Antonio Perez-Atayde, Stephan Voss, Justine Barletta, Alexandra Sala, Amber Miller, Martha Lodyga, Catherine Meador, Lori Wirth

Read the article.

Nieves Martinez Lago

Other articles featuring Nieves Martinez Lago on OncoDaily.

Alexandra Sala Amber Miller Antonio Perez-Atayde cancer Catherine Meador Jason  Hornick Justine Barletta Kartik Sehgal Lori Wirth Martha Lodyga Nieves Martinez Lago OncoDaily Oncology Stephan Voss Steven DuBois Thomas Roberts